[1]
Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: The dopamine system and its access points. Curr Top Behav Neurosci 2013; 13: 127-61.
[2]
Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-9.
[3]
Kenna GA. Pharmacotherapy of alcohol dependence: Targeting a complex disorder. Drug Discov Today Ther Strateg 2005; 2: 71-8.
[4]
Liu X, Jernigen C, Gharib M, Booth S, Caggiula AR, Sved AF. Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats. Behav Pharmacol 2010; 21: 153-60.
[5]
Khaled MA, Pushparaj A, Di Ciano P, Diaz J, Le Foll B. Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking. Neuropsychopharmacol 2014; 39(13): 3049-58.
[6]
Heidbreder CA, Gardner EL, Zheng Xiong Xi, et al. The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Rev 2005; 49: 77-105.
[7]
Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Effect of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav Brain Res 2001; 121: 189-97.
[8]
Baladi MG, Newman AH, France CP. Feeding condition and the relative contribution of different dopamine receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacol 2014; 231: 581-91.
[9]
Rogowski A, Rokicki D, Kostowski W, Bienkowski P. Relationship between dopamine D2 receptor-associated responses and operant ethanol self-administration in the rat: A factor analysis. Alcohol Alcohol 2003; 38: 305-9.
[10]
Liu X, Weiss F. Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: Differences in antagonist potency in previously ethanol-dependent versus non-dependent rats. J Pharmacol Exp Ther 2002; 300: 882-9.
[11]
Gremel CM, Cunningham CL. Involvement of amygdala dopamine and nucleus accumbens NMDA receptors in ethanol-seeking behavior in mice. Neuropsychopharmacol 2009; 34: 1443-53.
[12]
Moreira FA, Dalley JW. Dopamine receptor partial agonists and addiction. Eur J Pharmacol 2015; 752: 112-5.
[13]
Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; Feb; 47(1): 27-38.
[14]
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(7): 1159-72.
[15]
Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1): 13-23.
[16]
Li S, Zou Y, Liu L, Wu P, Lu L. Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats. Pharmacol Biochem Behav 2009; 92: 370-5.
[17]
Marinho EA, Oliveira-Lima AJ, Wuo-Silva R, et al. Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: A pre-clinical behavioural study. Int J Neuropsychopharmacol 2014; 17: 613-23.
[18]
Futamura T, Akiyama S, Sugino H, Forbes AD, McQuada R, Kikuchi T. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1115-9.
[19]
Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 2010; 30: 365-72.
[20]
Burda-Malarz K, Kus K, Ratajczak P, Czubak A, Hardyk S, Nowakowska E. Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats. Drug Chem Toxicol 2014; 37: 281-9.
[21]
Vergne DE, Anton RF. Aripiprazole: A drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets 2010; 9: 50-4.
[22]
Cunningham CL, Gremel CM, Groblewski PA. Drug-induced conditioned place preference and aversion in mice. Nat Protoc 2006; 4: 1662-70.
[23]
Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 1991; 564: 203-19.
[24]
Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacol 2005; 30: 339-49.
[25]
Ingman K, Kupila J, Hyytia P, Korpi ER. Effects of aripiprazole on alcohol intake in an animal model of high alcohol drinking. Alcohol 2006; 41: 391-8.
[26]
Dall’Olio R, Gaggi R, Voltattorni M, Tanda O, Gandolfi O. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviours. Behav Pharmacol 2002; 13: 633-8.
[27]
Bharal N, Pillai KK, Vohora D. Effects of sparfloxacin on CNS functions and urinary hydroxyproline in mice. Pharmacol Res 2006; 54: 111-7.
[28]
Ali A, Ahmad FJ, Pillai KK, Vohora D. Evidence of the antiepileptic potential of amiloride with neuropharmacological benefits in rodent models of epilepsy and behavior. Epilepsy Behav 2004; 5: 322-8.
[29]
Aguilar MA, Rodriguez-Arias M, Minarro J. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res Rev 2009; 59: 253-77.
[30]
Gonzales RA, Job MO, Doyon WM. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 2004; 103: 121-46.
[31]
Beninger RJ, Banasikowski TJ. Dopaminergic mechanism of reward-related incentive learning: focus on the dopamineD (3) receptor. Neurotox Res 2008; 14(1): 57-70.
[32]
Filip M, Papla I, Czepiel K. Role of D3 receptor in controlling the expression of cocaine sensitization in rats. Pol J Pharmacol 2002; 54: 687-91.
[33]
Duarte C, Biala G, Bihan CL, Hamon M, Theibot MH. Respective roles of dopamine D2 and D3 receptor in food seeking behavior in rats. Psychopharmacol 2003; 166: 19-32.
[34]
Vorel SR, Ashby Jr C.R., Paul M, Liu X, et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002; 22: 9595-603.
[35]
Ashby Jr C.R., Paul M, Gardener EL, Heidbreder CA, Hagan JJ. Acute administration of selective D3 receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003; 48: 154-6.
[36]
Jeanblanc J, He DY, McGough NNH, et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 2006; 26: 1457-64.
[37]
Audinot V, Newman-Tancredi A, Gobert A, et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 1998; 287: 187-97.
[38]
Davies MA, Sheffler DJ, and Roth BL. Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2003; 28(8): 1400-11.
[39]
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137-40.
[40]
Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-7.
[41]
Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 2007; 61: 582-90.
[42]
Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: Results from a pilot study. J Clin Psychopharmacol 2007; 27: 519-20.
[43]
Cunningham CL, Malott DH, Dickinson SD, Risinger FO. Haloperidol does not alter expression of ethanol-induced conditioned place preference. Behav Brain Res 1992; 50: 1-5.
[44]
Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: Recent developments. J Psychopharmacol 2005; 19: 408-13.
[45]
Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence. CNS Drugs 2008; 22: 367-88.
[46]
Biojone C, Casarotto PC, Resstel LB, Zangrossi Jr H., Guimares FS, Moreira FA. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. J Psychopharmacol 2011; 25: 801-7.
[47]
Richtand NM, Logue AD, Welge JA, et al. The dopamine D3 receptor antagonist nafadotride inhibit development of locomotor sensitization to amphetamine. Brain Res 2000; 867: 239-42.
[48]
Leite JV, Guimaraes FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008; 578: 222-7.
39
2